Ecnoglutide
XANO Pharmaceuticals\' GLP-1 Receptor Agonist
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
GLP-1 Targeting
- • Potent GLP-1 receptor activation
- • Sustained appetite suppression
- • Once-weekly injection
- • Track doses in Shotlee
Metabolic Effects
- • Improved glucose control
- • Insulin sensitivity benefits
- • Cardiometabolic improvements
- • Log labs in Shotlee
Clinical Promise
- • Competitive weight loss results
- • 16% in 24 weeks (Phase 2)
- • Global development pipeline
- • Monitor progress in Shotlee
Why This Matters
Ecnoglutide\'s Phase 2 results showing 16% weight loss in just 24 weeks are competitive with established GLP-1s. More options in the GLP-1 class mean more choices for patients and potentially better pricing.
Clinical Data
Highest dose group achieved approximately 16% mean weight loss over 24 weeks in Phase 2.
Side effect profile consistent with GLP-1 class. Generally well tolerated with dose escalation.
Side Effects
- • Nausea (dose-dependent)
- • GI discomfort
- • Decreased appetite
- • Track symptoms in Shotlee
Vital Protocol FAQs
What is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist showing approximately 16% weight loss in 24-week Phase 2 trials. Track your GLP-1 protocol in the Shotlee app.
How does it compare to Semaglutide?
Both are GLP-1 agonists. Ecnoglutide\'s 16% loss in 24 weeks is competitive, but head-to-head data is needed. Use Shotlee to compare your own results across medications.
Prepare for Better Protocol Outcomes
Track your protocol with Shotlee and make every decision from clean, visible data instead of guesswork.
🚀 Use Shotlee for Free